BOSTON SCIENTIFIC CORPORATION Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BOSTON SCIENTIFIC CORPORATION (BSX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$222.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2020-02-25
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $2.07B, a 1268.87% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was $151.00M.
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$222.00M.
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$188.00M, a 135.47% decline from fiscal 2017.
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $530.00M, a 509.20% increase from fiscal 2016.
- BOSTON SCIENTIFIC CORPORATION cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was $87.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$222.00M 10-K · filed 2020-02-25 | |||
| 2019-09-30 | -$153.00M 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $1.99B 10-Q · filed 2019-07-30 | |||
| 2019-03-31 | $2.07B 10-Q · filed 2019-04-29 | |||
| 2018-12-31 | -$188.00M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | -$37.00M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$23.00M 10-Q · filed 2019-07-30 | |||
| 2018-03-31 | $151.00M 10-Q · filed 2019-04-29 | |||
| 2017-12-31 | $530.00M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $202.00M 10-Q · filed 2018-10-29 | |||
| 2017-06-30 | -$11.00M 10-Q · filed 2018-07-31 | |||
| 2016-12-31 | $87.00M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |